308 related articles for article (PubMed ID: 17990351)
1. New approaches in angiogenic targeting for colorectal cancer.
Prat A; Casado E; Cortés J
World J Gastroenterol; 2007 Nov; 13(44):5857-66. PubMed ID: 17990351
[TBL] [Abstract][Full Text] [Related]
2. [Anti-angiogenic treatment and colorectal cancer].
André T; Tournigand C; Abbas F; Louvet C; de Gramont A;
Bull Cancer; 2007 Jul; 94 Spec No():S211-9. PubMed ID: 17846007
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic therapies for metastatic colorectal cancer.
Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
[TBL] [Abstract][Full Text] [Related]
4. Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.
Penland SK; Goldberg RM
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S74-80. PubMed ID: 15479483
[TBL] [Abstract][Full Text] [Related]
5. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Los M; Roodhart JM; Voest EE
Oncologist; 2007 Apr; 12(4):443-50. PubMed ID: 17470687
[TBL] [Abstract][Full Text] [Related]
6. Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
Collins TS; Hurwitz HI
Semin Oncol; 2005 Feb; 32(1):61-8. PubMed ID: 15726507
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study.
Kwon HC; Oh SY; Lee S; Kim SH; Kim HJ
World J Gastroenterol; 2007 Dec; 13(46):6231-5. PubMed ID: 18069765
[TBL] [Abstract][Full Text] [Related]
8. Update on angiogenesis inhibitors.
Zakarija A; Soff G
Curr Opin Oncol; 2005 Nov; 17(6):578-83. PubMed ID: 16224236
[TBL] [Abstract][Full Text] [Related]
9. Sequencing of antiangiogenic agents in the treatment of metastatic colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2014 Sep; 13(3):135-44. PubMed ID: 24768040
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab in the treatment of colorectal cancer.
Mulcahy MF; Benson AB
Expert Opin Biol Ther; 2005 Jul; 5(7):997-1005. PubMed ID: 16018743
[TBL] [Abstract][Full Text] [Related]
11. [Anti-angiogenic treatments in metastatic colorectal cancer: Does a continuous angiogenic blockade make sense?].
Jary M; Borg C; Bouché O; Kim S; André T; Bennouna J
Bull Cancer; 2015 Sep; 102(9):758-71. PubMed ID: 26232849
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
13. Integrating the anti-VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer.
Hurwitz H
Clin Colorectal Cancer; 2004 Oct; 4 Suppl 2():S62-8. PubMed ID: 15479481
[TBL] [Abstract][Full Text] [Related]
14. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
15. Targeted therapy in colorectal cancer.
Rajpal S; Venook AP
Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
[TBL] [Abstract][Full Text] [Related]
16. Biological agents versus chemotherapy in the treatment of colorectal cancer.
Eng C; Shalan N
Expert Opin Pharmacother; 2006 Jul; 7(10):1251-71. PubMed ID: 16805714
[TBL] [Abstract][Full Text] [Related]
17. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
18. [Role of angiogenesis inhibitors in the treatment of colorectal cancer].
Bodoky G
Magy Onkol; 2007; 51(2):139-44. PubMed ID: 17660870
[TBL] [Abstract][Full Text] [Related]
19. Recent concepts of antiangiogenic therapy.
Konno H; Yamamoto M; Ohta M
Surg Today; 2010 Jun; 40(6):494-500. PubMed ID: 20496129
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
